Metastatic Nasopharyngeal Carcinoma
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.
Metastatic Nasopharyngeal Carcinoma
DRUG: Penplimab Injection|DRUG: Antitinib Hydrochloride Capsules|DRUG: Gemcitabine
PFS, PFS defined as the time from the first dose until the first documented progressive disease (PD) or death from any cause., Baseline up to 2 years
Objective Response Rate（ORR）, Percentage of subjects achieving complete response (CR) and partial response (PR), Baseline up to 2 years|Disease Control Rate (DCR), Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD), Baseline up to 2 years|Overall survival (OS), OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up, Baseline up to 2 years|Time to Response (TTR), TTR defined as the time from randomization to the first recorded CR or PR, Baseline up to 2 years|Duration of Response (DOR), DOR defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurred first., Baseline up to 2 years|PD-L1 expression, Evaluating the correlation between PD-L1 expression and efficacy in tumor tissue samples., Tumor tissue samples must be provided to the research center prior to initial administration|Blood EBV level, Evaluate the correlation between the copy number of EBV DNA in the blood of subjects and their efficacy., Baseline up to 2 years|Evaluate the health-related quality of life (HRQoL) of subjects, Evaluate the health-related quality of life (HRQoL) of subjects using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire scale。The minimum values is 1，the maximum values is 4，and whether higher scores mean a worse outcome., Baseline up to 2 years
To evaluaate the efficacy and safety of the regimen incuding Penpulimab, Gemcitabine and Anlotinib in the treatment of metastatic nasopharyngeal carcinoma. Using Progression-Free-Survival as the primary endpoint.